Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data
Table 1
Baseline characteristics of patients.
Characteristics
Total patients (n = 243)
Test sets (n = 175)
Validation sets (n = 68)
values
Age (years)
50.24 ± 11.1
51.1 ± 10.3
49.4 ± 12.3
0.257
BMI
24.2 ± 3.5
24.4 ± 4.5
24.0 ± 3.5
0.664
Menopausal status
0.394
Premenopausal
118
82/46.9%
36/52.9%
Postmenopausal
125
93/53.1%
32/47.1%
Clinical T stage
0.705
1
33
26/14.9%
7/10.3%
2
145
105/60.0%
40/58.8%
3
32
22/12.6%
10/14.7%
4
33
22/12.6%
11/16.2%
Clinical N stage
0.598
1
128
95/54.3%
33/48.5%
2
81
55/31.4%
26/38.2%
3
34
25/14.3%
9/13.2%
Histologic type
0.998
IDC
222
160/91.4%
62/91.2%
ILC
7
5/2.9%
2/2.9%
Other
14
10/5.7%
4/5.9%
Breast surgery
0.389
BCS
89
67/38.3%
22/32.4%
Mastectomy
154
108/61.7%
46/67.6%
LN surgery
0.835
SLNB
3
2/1.1%
1/1.5%
ALND
240
173/98.9%
67/98.5%
ypT stage
0.455
0
16
12/6.9%
4/5.9%
1
122
90/51.4%
32/47.1%
2
82
59/33.7%
23/33.8%
3
14
10/5.7%
4/5.9%
4
9
4/2.3%
5/7.4%
ypN stage
0.348
0
46
36/20.6%
10/14.7%
1
95
68/38.9%
27/39.7%
2
60
45/25.7%
15/22.1%
3
42
26/14.9%
16/23.5%
Note. Unless otherwise stated, data refer to the number of patients or the percentage of the total number of patients. IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; BCS = breast conserving surgery; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection.
